Secarna Pharmaceuticals announces the acquisition of LNAplus(TM) based antisense drug candidates by Lipigon Pharmaceuticals
Secarna and Lipigon jointly generated candidates for cardiovascular and metabolic diseases in a target validation and drug discovery collaboration Lipigon...